Drug Profile
Research programme: centrally acting opioid analgesics - ChironWell
Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator ChironWells
- Class Morphinans
- Mechanism of Action Opioid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Pain in Austria (Parenteral) (ChironWells pipeline; September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Pain in Austria (Parenteral)
- 25 Apr 2016 Preclinical trials in Pain in Austria (Parenteral) prior to April 2016